RBC Capital raised the firm’s price target on Alnylam (ALNY) to $500 from $435 and keeps an Outperform rating on the shares. The latest script data came out late last week and suggests another very impressive month for Amvuttra, which looks to be is marching toward another strong beat for Q3, the analyst tells investors in a research note. Valuation remains the key debate, but the firm remains a buyer given a drug that continues to deliver and a market where the ceiling has yet to be appreciated, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target raised to $520 from $453 at BofA
- Alnylam Pharma: Promising Growth Driven by ATTR-CM Franchise and siRNA Platform Expansion
- Alnylam Pharma Executes Note Repurchase Transactions
- Alnylam Pharma Announces $500M Convertible Notes Offering
- Alnylam announces $500M convertible senior notes offering